GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update. The company is advancing its lead program, GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine candidate for mpox and smallpox, toward a planned pivotal immunobridging study under an expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA).
During the second quarter, GeoVax advanced multiple operational initiatives supporting the expected fourth-quarter initiation of the study. These activities included clinical study readiness, manufacturing preparedness, and utilization of previously manufactured and released cGMP clinical trial material. The company also advanced its AGE1 continuous cell-line manufacturing platform to support future commercial-scale MVA vaccine production and engaged with government, public health, and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
"During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study," said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. "Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense."
GeoVax also continues advancing Gedeptin, its investigational gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism and immune activation profile may complement PD-1-based therapies, such as Merck's Keytruda, by improving responsiveness in immunologically resistant tumors. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4,426,578 for the second quarter of 2026, compared to a net loss of $5,369,783 for the same period in 2025. Research and development expenses decreased to $3,110,508 from $4,728,998, primarily due to lower costs associated with discontinued activities related to the BARDA contract and reduced spending on GEO-CM04S1 clinical activities. General and administrative expenses fell to $1,331,564 from $1,542,190, reflecting lower investor relations consulting costs and reduced stock-based compensation. The company reported cash balances of approximately $3.1 million as of June 30, 2026.
In May 2026, GeoVax announced a strategic reprioritization of its development portfolio to concentrate resources on GEO-MVA and Gedeptin, discontinuing active development of its GEO-CM04S1 COVID-19 vaccine candidate due to the evolution and contraction of the global COVID-19 vaccine market. The decision was not related to any safety or efficacy concerns.
GeoVax believes GEO-MVA is uniquely positioned to help address the growing need for diversified global MVA vaccine manufacturing capacity. The company is prioritizing resources toward programs offering the strongest combination of clinical differentiation, regulatory clarity, and commercial opportunity. Additional information is available in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.
